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Acute Myeloid Leukemia
Assessment of submicroscopic genetic lesions
by single nucleotide polymorphism arrays in
a child with acute myeloid leukemia and
FLT3-internal tandem duplication
The same FLT3-internal tandem duplication (ITD)
positive clone was detected at diagnosis and relapse,
but not at birth, in a child with M1 acute myeloid
leukemia. Single nucleotide polymorphism arrays
demonstrated that chromosome 13 acquired uni-
parental disomy, in association with del(9q), repre-
sented a progressive event in the course of the dis-
ease, and it was responsible for the homozygous
FLT3-ITD at relapse. 
Haematologica 2006; 91:998-1000
(http://www.haematologica.org/journal/2006/07/998.html)
We studied the clonal evolution from birth to diagnosis
and relapse in a child with FLT3-internal tandem duplica-
tion (ITD)-positive acute myeloid leukemia (AML) who
experienced two early relapses and for whom we fortu-
itously had a cord blood sample. FLT3-ITD was used as a
minimal residual disease marker, and to backtrack the
leukemic cells into the cord blood.
The patient was a female diagnosed at 6 years of age
with AML-M1. At diagnosis, the patient’s bone marrow
karyotype was normal; the molecular screening showed
FLT3-ITD mutation, a wild type NPM1 sequence and neg-
ativity for CBFB-MYH11 and CBFA-ETO fusion genes. She
underwent autologous bone marrow transplantation in
complete disease remission following induction therapy
Figure 1. Clonal evolution of chromosome 13 abnormalities. A) A schematic diagram of SNP calls on chromosome 13. Copy number ratio
was calculated for each SNP using a ratio of the signals from the germ line (cord blood) and leukemia. For each SNP a mean number of
copies in a window of 10 adjacent SNP was used. Green lines represent SNP calls retained in the germ line and the leukemia, with light
green representing heterozygous and dark green homozygous SNP. Red lines represent loss of call compared with the germ line. In the
relapse sample, there is complete loss of heterozygosity (LOH) without a change in the copy number suggesting UPD. B) FISH analysis with
the chromosome 13q14 LSI D13S319 SpectrumOrange probe on the relapse sample shows the presence of two signals, indicating the
retention of two alleles on chromosome 13, despite the LOH, thus confirming UPD. C) Agarose gel electrophoresis of PCR-amplified FLT3
gene indicates the loss of wild type FLT3 allele at relapse (lower band), together with progressive increase of FLT3-ITD (upper band). At diag-
nosis, both alleles were present. Remission phase samples harboring the wild type allele are shown. The wild type band at relapse might
be due to the presence of a low number of non-leukemic cells. D) Quantitative analysis of the FLT3-ITD mutation by RQ-PCR confirms the
absence of the FLT3-ITD positive clone during complete remission, and its reappearance before the relapse. Normalized copy numbers of
FLT3-ITD with respect to the albumin gene are shown on the Y-axis. TP1=day +15, TP2=day +21; TP3=day +32, TP4= +2 months (end of
induction), TP5= +4 months after diagnosis; days after autologous bone marrow transplantation are indicated.
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(AIEOP-02 AML protocol). However, 3.5 months later the
patient relapsed. Four months after an allogeneic bone mar-
row transplant, she had a second relapse and died of dis-
ease progression. 
FLT3-ITD monitoring from diagnosis to relapse was per-
formed by a patient-specific highly sensitive (10-4) real-time
quantitative (RQ)-polymerase chain reaction (PCR),1 show-
ing a progressive decrease of minimal residual disease
(Figure 1, panel D). The same FLT3-ITD clone re-emerged
at relapse, suggesting that the leukemic clone responsible
for the first diagnosis was stable and could be used for
backtracking the leukemia into the cord blood. 
When tested by highly sensitive RQ-PCR, the cord blood
DNA resulted negative for the FLT3-ITD mutation, consis-
tent with the current hypothesis that FLT3-ITD is a second-
ary event in leukemogenesis.2 This is the first direct report
on post-natal occurrence of FLT3-ITD.
We then applied a 10K single nucleotide polymorphism
(SNP) array approach (Affymetrix, Inc., Santa Clara, CA,
USA) to search for genome-wide loss of heterozygosity
and/or copy number changes of genes involved in tumor
evolution,3 comparing cord blood, diagnostic and relapse
samples. SNP arrays on the relapse sample showed chro-
mosome 13 uniparental disomy (UPD) (Figure 1, panel A),
confirmed by fluorescent in situ hybridization (FISH) with a
13q14.3 LSI D13S319 SpectrumOrange probe (Vysis,
Abbott GmbH, Germany) (Figure 1, panel B). We assume
that, through the evolution of the disease from diagnosis to
relapse, chromosome 13 harboring the FLT3-ITD had
undergone non-disjunction. The leukemic cells with chro-
mosome 13 UPD and FLT3-ITD homozygosity may have
acquired a clonal advantage over those with the wild type
FLT3 allele. This finding was also confirmed by qualitative
PCR, as shown in Figure 1, panel C. Agarose gel elec-
trophoresis of FLT3-ITD PCR products indicated the
increase of the ITD PCR amplification over the wild type
band. Acquired UPD has been recently demonstrated in
approximately 20% of AML4 and UPD on chromosome 13
was detected by SNP arrays in three out of five relapse sam-
ples from FLT3-ITD positive patients.5 In addition to
UPD13, an interstitial deletion was found by SNP arrays on
chromosome 9q21.32-q33.2 (Figure 2, panel A), confirmed
by FISH with BAC-derived probe RP11-402M4 located on
9q31.1 (Invitrogen, Paisley, UK) (Figure 2, panel B).
Unfortunately, no information about the karyotype was
available on the relapse sample to exclude the presence of
structural chromosomal rearrangements. Del(9q) has been
reported in about 2% of AML cases, frequently associated
with t(8;21) and rarely with t(15;17).6 The presence of
tumor suppressor genes potentially involved in disease pro-
gression on the 9q deleted chromosomal fragment must be
further explored.
We hypothesize that a still unknown primary event, such
as a mutation in a proto-oncogene, hit the patient’s
Figure 2. Analysis of chromosome 9 deletion on a relapse sample. A. A schematic diagram of SNP calls on chromosome 9. Copy num-
ber ratio was calculated for each SNP using a ratio of the signals from the germ line (cord blood) and leukemia. For each SNP a mean
number of copies in a window of 10 adjacent SNP was used. Green lines represent SNP calls retained in the germ line and the leukemia,
with light green representing heterozygous and dark green homozygous SNP. Red lines represent loss of call compared with the germ
line. In the relapse sample, there is complete LOH with decrease in the copy number on chromosome 9q21.32-q33.2, suggesting inter-
stitial deletion. B. FISH analysis with BAC probe RP11-402M4 shows only one signal, validating SNP array results on 9q deletion.
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leukemia stem cell and that the FLT3-ITD occurred as a fur-
ther step, affecting the same stem cell population.
Subsequently, the cell harboring FLT3-ITD accumulated
both chromosome 13 UPD and 9q deletion, giving rise to
the subsequent relapses.
In summary, by using a combined SNP array and RQ-
PCR approach we have been able to indicate the post-natal
origin of the FLT3-ITD mutation observed at diagnosis in
this AML patient, and to demonstrate the occurrence of
loss of heterozygosity as a mechanism of disease progres-
sion, which may be associated with both copy number
changes -del(9q)- or UPD (FLT3-ITD homozygosis). We are
aware that the primary event(s) giving rise to leukemia in
association with FLT3-ITD mutation may be represented
by aberrations not detected by SNP array analysis, and
affect genes involved in differentiation pathways, as
expected from the model of co-operative mutations.7 Other
methods must be applied in order to find these class II
putative mutations. 
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